Medtronic Raises 2027 Outlook Amid Surge in Heart Device Demand

Medtronic has revised its fiscal 2027 revenue and profit forecasts upward, buoyed by heightened demand for its heart devices used in complex cardiovascular procedures. This adjustment reflects the company's confidence in its expanding portfolio and strategic investments, announced on Tuesday.

Increased Demand for Heart Devices

The medical technology giant now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from its previous estimate of 6.75% to 7.25%. The company has also raised the lower end of its adjusted per-share profit forecast to $5.94, maintaining the upper limit at $6. This optimistic outlook is driven by robust sales in its cardiovascular segment, which saw a 19.5% increase to $3.93 billion in the last quarter, largely due to the success of its pulsed field ablation portfolio designed to treat irregular heart rhythms.

Strategic Investments and Market Expansion

Medtronic is not only banking on current product demand but is also investing heavily in future growth. It announced an $80 million investment in Pi-Cardia, a heart-valve repair device manufacturer, with an option to acquire the company for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the United States. CEO Geoff Martha emphasized the importance of these investments, noting the low penetration of soft tissue robotic surgery in emerging markets, which Medtronic aims to address with Cornerstone's Sentire system.

Financial Performance and Market Confidence

Medtronic's recent financial results exceeded market expectations, reporting an adjusted quarterly per-share profit of $1.45 on revenues of $9.76 billion, surpassing analysts' predictions of $1.39 per share on $9.55 billion in sales. CFO Thierry Pieton highlighted that tariff refunds nearly offset duties paid during the quarter, though these are not factored into future projections.

Geoff Martha, during a post-earnings call, expressed confidence not only in the company's quarterly performance but also in the broad-based contributions from across its business segments. He stressed the company's strategy of targeting high-growth areas within medtech, which promise substantial patient pools and market segments.

With these strategic moves and strong financial performance, Medtronic is positioning itself for sustained growth, leveraging its investments and product innovations to capture a larger share of the expanding global market for cardiovascular and robotic surgical devices.